Table of Contents

• Why This Article Exists
• TIRADS: The Scoring System for Your Ultrasound
• TIRADS 1 Through 5: What Each One Means for You
• Bethesda: The Scoring System for Your FNAC Biopsy
• Bethesda 1 Through 6: What Each One Means for You
• Putting TIRADS and Bethesda Together: How Your Doctor Makes a Plan
• Bookmark This Page

 

1. Why This Article Exists

Because you are holding a thyroid report right now and you cannot understand it.

The report says “TIRADS 3” or “Bethesda II” or “ACR TIRADS category 4” and you have no idea whether to be relieved or terrified. You Google it. The results are a mix of medical jargon, contradictory forum posts, and cancer statistics that were never meant for a patient audience. By midnight, you have diagnosed yourself with something that was never in the report.

This article translates both scoring systems into plain language. What each number means. What it does NOT mean. What your doctor will likely recommend next. And most importantly, whether you should be worried or not. Save this page. Come back to it every time you get a new report. It is meant to be a reference, not a one-time read.

 

2. TIRADS: The Scoring System for Your Ultrasound

When a radiologist performs a thyroid ultrasound, they do not just measure the nodule. They assess it. They look at specific features: is it solid or cystic? What shape is it? Are the borders smooth or irregular? Are there calcifications inside? How much blood flow does it have?

Based on these features, the nodule is assigned a TIRADS score (Thyroid Imaging Reporting and Data System). Think of TIRADS as a traffic light system for thyroid nodules. It tells you how suspicious the nodule looks on imaging, and it guides whether a biopsy (FNAC) is recommended.

There are slightly different TIRADS versions used by different professional bodies (ACR TIRADS, EU-TIRADS, K-TIRADS), but the basic principle is the same across all of them: higher number means more suspicion.

3. TIRADS 1 Through 5: What Each One Means for You

TIRADS 1: Normal thyroid. No nodule found. The gland looks healthy. There is nothing to investigate further. If your report says TIRADS 1, you can stop worrying. You do not need FNAC. You do not need follow-up for the thyroid specifically.

TIRADS 2: Benign. A nodule is present, but its features are clearly benign. This includes simple cysts, spongiform nodules, and other patterns that have an extremely low malignancy risk (under 2%). No FNAC is needed in most cases. Periodic ultrasound follow-up every 12 to 24 months is typically sufficient. If you see TIRADS 2, exhale. This is the best possible finding when a nodule exists.

TIRADS 3: Mildly suspicious / Low suspicion. The nodule has some features that are not perfectly clean but is still overwhelmingly likely to be benign. Malignancy risk is under 5%. Whether FNAC is recommended depends on size: for nodules under 2.5 cm, most guidelines suggest follow-up ultrasound rather than immediate biopsy. For larger nodules, FNAC may be recommended to confirm what imaging already strongly suggests. TIRADS 3 is a yellow light, not a red one. It says “proceed with awareness,” not “emergency.” We covered this in our TIRADS 3 video script as well.

TIRADS 4: Moderately suspicious. The nodule has one or more features that raise concern: solid composition with hypoechoic appearance, irregular margins, microcalcifications, or taller-than-wide shape. Malignancy risk ranges from approximately 5 to 20% depending on the specific sub-classification. FNAC is recommended for nodules above 1 to 1.5 cm. This is the category where the biopsy becomes important because the imaging alone cannot give a definitive answer. TIRADS 4 does not mean cancer. It means “we need to check with a needle.”

TIRADS 5: Highly suspicious. The nodule has multiple concerning features. Malignancy risk is above 20%, and in some sub-categories significantly higher. FNAC is strongly recommended, usually even for smaller nodules. TIRADS 5 is serious and should be evaluated promptly. But even at TIRADS 5, not every nodule turns out to be cancer. The FNAC result is what gives the definitive answer.

The key takeaway: TIRADS tells you how suspicious the nodule looks. It does not tell you what the nodule is. Only FNAC (the biopsy) can do that.

 

4. Bethesda: The Scoring System for Your FNAC Biopsy

If your TIRADS score leads to an FNAC, the cells collected by the needle are examined by a cytopathologist (a doctor who specialises in reading cell samples). Based on what they see under the microscope, the sample is classified using the Bethesda System for Reporting Thyroid Cytopathology.

Think of Bethesda as the second checkpoint. TIRADS told you how the nodule looked from the outside. Bethesda tells you what the cells look like from the inside. Together, they give your doctor a clear picture of what is happening and what should happen next.

 

5. Bethesda 1 Through 6: What Each One Means for You

Bethesda I: Non-diagnostic / Inadequate. The sample collected did not contain enough cells to make a diagnosis. This is not a bad result. It is a no-result. It can happen because the nodule was mostly cystic (fluid, not cells), because the needle missed the target, or because the sample was poorly prepared. The standard recommendation is to repeat the FNAC. If you get Bethesda I, it does not mean something is wrong with the nodule. It means the test needs to be done again.

Bethesda II: Benign. The cells look normal. The nodule is benign. Malignancy risk is under 3%. This is the result you want. For most patients, this means monitoring with periodic ultrasound (every 12 to 18 months) rather than treatment, unless the nodule is large, growing, or causing symptoms. If Bethesda II is your result and your nodule is symptomatic, ablation becomes an excellent option because you now know the nodule is safe to treat without removing it.

Bethesda III: Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS). The grey zone. The cells do not look clearly benign, but they are not clearly suspicious either. Malignancy risk is approximately 10 to 30%. This is the result that causes the most anxiety. The usual recommendation is to repeat the FNAC in 6 to 12 weeks with an experienced cytopathologist, or to consider molecular testing if available. Surgery is sometimes recommended but is not always necessary at this stage. We covered Bethesda 3 in detail in our video scripts.

Bethesda IV: Follicular Neoplasm / Suspicious for Follicular Neoplasm. The cells show a follicular pattern that could be either a benign follicular adenoma or a follicular carcinoma. The microscope cannot tell the difference because the distinction depends on whether the tumour has invaded its capsule, which can only be assessed by examining the whole nodule after surgical removal. Malignancy risk is 25 to 40%. Diagnostic surgery (usually thyroid lobectomy) is the standard recommendation, though molecular testing can help stratify risk further in some cases. We covered this in detail in our Bethesda 4 video script.

Bethesda V: Suspicious for Malignancy. The cells look very likely to be cancerous, but the sample falls just short of a definitive diagnosis. Malignancy risk is 60 to 75%. Surgery (typically total thyroidectomy or lobectomy depending on clinical context) is strongly recommended. This is not a result to delay or re-biopsy. It requires prompt surgical evaluation and planning.

Bethesda VI: Malignant. The cells are diagnostic of cancer. Most commonly papillary thyroid carcinoma. Malignancy risk is 97 to 99%. Surgery is the standard treatment. However, even at Bethesda VI, the prognosis for most thyroid cancers (particularly papillary carcinoma) is excellent. Thyroid cancer is one of the most treatable cancers in medicine. A Bethesda VI result is serious, but it is not a death sentence. It is a clear instruction to act.

 

6. Putting TIRADS and Bethesda Together: How Your Doctor Makes a Plan

Your TIRADS score determines whether you need an FNAC. Your Bethesda result determines what happens next. Together, they create a roadmap.

TIRADS 2 + no FNAC needed: Monitor. Repeat ultrasound in 12 to 24 months. No intervention required unless symptoms develop.

TIRADS 3 or 4 + Bethesda II: The nodule looked mildly or moderately suspicious on imaging, but the biopsy confirmed benign. Continue monitoring. If the nodule is large or symptomatic, ablation is an excellent option because you have confirmation that it is safe to treat without surgery.

TIRADS 4 + Bethesda III: Imaging was suspicious, biopsy was indeterminate. Repeat FNAC with an experienced cytopathologist. Consider molecular testing. Surgery may ultimately be needed but should not be the automatic next step without exploring other avenues.

Any TIRADS + Bethesda V or VI: Surgery. These results are clear enough to act on. Your doctor will refer you to a thyroid surgeon and plan the appropriate operation.

The scoring systems exist to prevent two problems: unnecessary surgery on benign nodules, and delayed surgery on cancerous ones. When used properly, they protect you from both extremes.

 

7. Bookmark This Page

This article is not meant to be read once and forgotten. It is meant to be saved and revisited every time you get a thyroid report.

Your next ultrasound says TIRADS 3? Come back here. Remind yourself what that means. Your FNAC comes back Bethesda II? Come back here. Understand what the next step is. Your doctor recommends something and you want to cross-check whether it makes sense? Come back here.

TIRADS and Bethesda are not scary systems. They are protective ones. They exist to give you and your doctor a shared language for making the right decision. Now you speak that language too.

To discuss your thyroid report with Dr. Parul Garg:

Website: Book an Appointment

Phone / WhatsApp: +91-9211978100

Email: [email protected]

A TIRADS score without context is just a number. A Bethesda result without explanation is just a word. Now you have both the numbers and the explanation. Use them.